SlideServe
Télécharger Obtenir Pro
Menu
Accueil Pro
Préférences
ApparenceLight Aide et commentaires
© SlideServe · v2026

Preclinical Safety and Efficacy Evaluation of Recombinant BCG Pasteur Vaccine

tallulah-williamson avatar
tallulah-williamson
11 diapositives · 258 Views · Oct 30, 2014

This study evaluates the safety, efficacy, and immunogenicity of the recombinant rBCG Pasteur B vaccine compared to traditional BCG. Conducted in animal models including mice, guinea pigs, and non-human primates, the objective was to assess reactogenicity, toxicity, and protective efficacy against Mycobacterium tuberculosis. Key methods included evaluating general health, body weight, immune response (TNF, IL-2, IFN-γ), and bacterial burden post-immunization. The findings suggest promising safety and immunogenic profiles, indicating effective cell-mediated immunity and enhanced survival in challenging conditions.

#preclinical safety and efficacy evaluation of recombinant bcg pasteur vaccine #preclinical safety and efficacy evaluation of recombinant bcg pasteur vaccine ppt #powerpoint #presentation
Preclinical Safety and Efficacy Evaluation of Recombinant BCG Pasteur Vaccine - slide 1
01 / 11Preclinical Safety and Efficacy Evaluation of Recombinant BCG Pasteur Vaccine
1 / 17

Télécharger la présentation

Preclinical Safety and Efficacy Evaluation of Recombinant BCG Pasteur Vaccine
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation

  1. Preclinical evaluation of safety, efficacy, immunogenicity of a recombinant rBCG Pasteur B vaccine Group B4 March 16, 2011 Adane Miheret, Tewodros Tariku

  2. Pre-clinical study • Objective • To assess the safety (Reactogenecity and toxicity) and tolerability of rBCG Pasteur B vaccine compared to BCG • To assess the immunogenicity of rBCG Pasteur B vaccine compared to BCG • To assess the protective efficacy of rBCG Pasteur B vaccine compared to BCG

  3. Vaccine • This rBCG, a substitute for BCG, is prophylactic vaccine is intended to be used at birth to prevent infection from Mycobacterium tuberculosis. • Source of the vaccine: PASTEUR B LAB • Vaccine composition: rBCG∆mbtB∆UreC:pfoA-85AB-PPE44-DA-1 • Vaccine reconstitution: • Vaccine dose: • 5x 105, 5x106 , 5x107cfu • Number of dose: 1 dose • Route of immunization: Subcutaneous (mice and guinea pig) and Intradermal (NHP

  4. 2. Animal studies

  5. Flow chart Vaccine (n=105/105/6) BCG (n=105/105/6) Mice, Guinea Pigs & NHP Low Medium High Dose Route of immunization Subcutaneous (mice and Guinea pig) Intradermal (NHP) • Safety (5/group) • General health • Body weight • Immunogenicity (5/group) • Luminex • Flow cytometry • Protection (5 /group) • Survival time • Pathology • Weight change • Bacterial burden TNF, IL-2, IFN-γ, IL-10, TGF-β, IL-10, IL-4

  6. 3. Safety and toxicity testing in Mice and Guinea pig rBCG Immunocompromised (SCID) mice (n=30) Sacrificed for pathological examination and check for clearance of the vaccine (spleen, lung & liver) BCG 1d 2wk 8wk 12wk 16 wk rBCG Immunocompetent Mice (n=30) BCG • follow • General health status • Weight loss • Hematology • Clinical chemistry • Histopathology rBCG Guinea pig (n=30) BCG

  7. 4. Immunogenicity studies in animal models (Mice and Guinea Pigs) 4 week Vaccine (n=15) vaccination BCG (n=15) Sacrifice mice and homogenate the spleen and collect cells • Parameters to be measured • IL-2, IFN-γ, TNF-α, IL-10, IL-4, IL-17 producing CD4 and CD8 T cells = Sacrifice time

  8. 4. Efficacy studies in animal models (Mice, Guinea Pigs and NHP) Mice &Guinea Pigs (n=120) 4 week n=5 12 week n=5 BCG (n=60) vaccine 4 week (challenge) 8 week n=5 24 week n=5 Vaccine (n=60) NHP= 6 vaccine 6 week (challenge) 24 week n=3 40 week n=3 • Parameters to be measured • Bacterial burden (lung, spleen, liver) • Histopathological examination of lung, spleen, and liver • Body weight = Sacrifice time

  9. 5. Recommendation/ Expectedoutcomes • Safety profile of the new vaccine is excellent even in immunocompromised animals. • The vaccine would be very immunogenic and elicit protective Cell Mediated Immunity (CMI) polarized to Th1 type of response. • The new vaccine would enhance survival of Guinea pig infected with high dose of H37Rv with a marked reduction in bacterial load in different organs.

  10. Thank you for your attention!